These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11586100)

  • 1. Molecular pathways that modify tumor radiation response.
    Pervan M; Pajonk F; Sun JR; Withers HR; McBride WH
    Am J Clin Oncol; 2001 Oct; 24(5):481-5. PubMed ID: 11586100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition: a novel approach to cancer therapy.
    Adams J
    Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors as new anticancer drugs.
    Adams J
    Curr Opin Oncol; 2002 Nov; 14(6):628-34. PubMed ID: 12409653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting proteasomes: trash to treasure.
    Sussman HE
    Drug Discov Today; 2003 Oct; 8(19):866-8. PubMed ID: 14554007
    [No Abstract]   [Full Text] [Related]  

  • 8. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    An WG; Hwang SG; Trepel JB; Blagosklonny MV
    Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
    Giuliano M; D'Anneo A; De Blasio A; Vento R; Tesoriere G
    Ital J Biochem; 2003 Jun; 52(2):112-21. PubMed ID: 14677428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
    Mitra-Kaushik S; Harding JC; Hess JL; Ratner L
    Blood; 2004 Aug; 104(3):802-9. PubMed ID: 15090453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.
    Lee C; Waldman T
    Cancer Biol Ther; 2003; 2(6):700-1. PubMed ID: 14688480
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
    Orlowski RZ; Dees EC
    Breast Cancer Res; 2003; 5(1):1-7. PubMed ID: 12559038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
    Ling YH; Liebes L; Ng B; Buckley M; Elliott PJ; Adams J; Jiang JD; Muggia FM; Perez-Soler R
    Mol Cancer Ther; 2002 Aug; 1(10):841-9. PubMed ID: 12492117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
    Williams S; Pettaway C; Song R; Papandreou C; Logothetis C; McConkey DJ
    Mol Cancer Ther; 2003 Sep; 2(9):835-43. PubMed ID: 14555702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
    Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the ubiquitin-proteasome pathway in breast cancer.
    Cardoso F; Ross JS; Picart MJ; Sotiriou C; Durbecq V
    Clin Breast Cancer; 2004 Jun; 5(2):148-57. PubMed ID: 15245620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.